Health Technology Brief

supporting sound, evidence-based decision making

HT Briefs are concise technology assessment reports that provide an overall evaluation of the potential clinical and economic impact of new technologies
that are in the early stages of dissemination or of existing technologies that are being used for new applications.

View a sampling of our HT Briefs.

UroLift System (NeoTract Inc.) for Treatment of Benign Prostatic Hyperplasia

November 9, 2017 Health Technology Brief

Health Problem: Benign prostatic hyperplasia (BPH) is an enlargement or growth of the prostate that affects approximately 8 million men in the United States, including 30% of men older than 50 years of age and nearly 70% of men older than 70 years of age. The enlarged prostate restricts the urethra and applies pressure on the base of the bladder. This restriction of the urethra can result in clinical features, including an enlarged prostate and mild-to-severe lower urinary tract symptoms (LUTS), such as obstruction, incomplete emptying, intermittency, weak stream, hesitancy, frequency, urgency, and nocturia. Technology Description: The UroLift System is a...

Intravenous Immunoglobulin for Treatment of Intractable Epilepsy in Pediatric Patients

November 2, 2017 Health Technology Brief

Health Problem: Intractable epilepsy is diagnosed in 5% to 20% of pediatric patients with new-onset epilepsy. If uncontrolled, seizures in childhood may have a detrimental or even catastrophic impact on the developing brain. A connection has been made between inflammatory processes and neurological disease, including epilepsy, which may present new therapeutic approaches. Technology Description: Intravenous immunoglobulin (IVIG) is a purified blood product pooled from thousands of human blood donors. When provided in high doses, IVIG has an immunomodulatory effect, although its precise mechanism of action remains unclear. IVIG is increasingly being used as a therapeutic option for a variety of neurological...

Raindrop Near Vision Inlay (ReVision Optics Inc.) for Presbyopia

November 2, 2017 Health Technology Brief

Health Problem: Presbyopia is an age-related loss of accommodation in the lens of the eye that impairs the ability of the eye to change its optical power. The treatment goals for patients with presbyopia are restoration of near vision and a comfortable reading experience for the patient. Technology Description: The Raindrop Near Vision Inlay is a biocompatible clear hydrogel corneal inlay that reshapes the central region of the cornea to provide a zone of increased power for focusing on near objects, improving near vision. Controversy: Among people with presbyopia, there is a higher demand for spectacle independence. Surgical treatment options are invasive,...

iFuse Implant System (SI-Bone Inc.) for Sacroiliac Joint Fusion for Treatment of Sacroiliac Joint Dysfunction

November 2, 2017 Health Technology Brief

Health Problem: Sacroiliac joint (SIJ) dysfunction is characterized by the malalignment or abnormal movement of the SIJ causing pain and disability, and may be caused by trauma, inflammatory arthritis, osteoarthritis, pregnancy, or prior lumbar spinal fusion. Technology Description: The iFuse implant system consists of sterile, rigid, titanium rods that have a triangular cross section to minimize rotation and maximize surface area of the SIJ. Fusion with the iFuse implant is carried out through a minimally invasive procedure. Controversy: SIJ fusion via open surgery may provide pain relief but has many disadvantages, including: a large incision; bone harvesting and grafting; long operative times;...

Impella 2.5 System (Abiomed Inc.) for Cardiac Support in Patients Undergoing High-Risk Percutaneous Coronary Intervention

October 17, 2017 Health Technology Brief

Health Problem: Patients undergoing percutaneous coronary intervention (PCI) may be considered high risk based on a variety of factors, including advanced age, comorbidities, and lesion-specific characteristics. Patients undergoing high-risk PCI (HRPCI) may require mechanical circulatory support (MCS) during the PCI procedure to prevent adverse events and improve clinical outcomes. Technology Description: The Impella 2.5 is an intravascular, nonpulsatile axial blood pump indicated for temporary use during HRPCI. It is inserted percutaneously, usually through the femoral artery, and threaded into the left ventricle, where it pumps blood into the aorta at a rate of up to 2.5 liters per minute. Controversy: Controversies revolve...